Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Upcoming NCRI AML subgroup trials

Charles Craddock • 10 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Venetoclax
EVOLVE

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, discusses the key news and updates from the NCRI acute myeloid leukemia (AML) subgroup, including the EVOLVE study investigating the benefit of adding a FLT3 inhibitor into a venetoclax regimen in older unfit acute myeloid leukemia (AML) by Paresh Vyas and Mike Dennis. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Charles Craddock

2:14
Addressing the high rate of disease relapse following alloSCT in patients with AML
Charles Craddock • 10 Dec 2023
1:32
Stem cell transplantation conditioning in AML: making the decision between MAC and RIC
Charles Craddock • 10 Dec 2023
1:22
The UK Impact Transplant Trials Network: a national strategy to accelerate delivery of alloSCT RCTs
Charles Craddock • 10 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

6:38
Key papers in cardio-oncology from 2023 of relevance to hematologists
Alexander Lyon • 25 Apr 2024
7:50
The ESC guidelines on cardio-oncology: incorporating the guidelines into clinical practice
Alexander Lyon • 25 Apr 2024
1:56
Approaching treatment selection and sequencing with the recent influx of BTK inhibitors in CLL
Dima El-Sharkawi • 28 Apr 2024
1:17
Using an AI model to quantify under-utilization of alloSCT for AML in the UK
Thomas Coats • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals